Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1, Open Label Clinical Trial to Treat Stage IV Cancer Patients With Multiple Patient-specific Mutated Cell Surface Proteins With Chimeric Antibodies

NCT07783620 is registered in ClinicalTrials.gov with Centre hospitalier de l'Université de Montréal (CHUM) as lead sponsor.

NCT NCT07783620
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07783620 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1, Open Label Clinical Trial to Treat Stage IV Cancer Patients With Multiple Patient-specific Mutated Cell Surface Proteins With Chimeric Antibodies
Lead sponsor
Centre hospitalier de l'Université de Montréal (CHUM)
Phase
Phase 1
Overall status
Not yet recruiting
Start date
December 31, 2026
Completion date
December 31, 2031
Enrollment
16 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

soft tissue cancer